Literature DB >> 15065824

Primary pulmonary hypertension in families with hereditary haemorrhagic telangiectasia.

S A Abdalla1, C J Gallione, R J Barst, E M Horn, J A Knowles, D A Marchuk, M Letarte, J H Morse.   

Abstract

Primary pulmonary hypertension (PPH) is a rare but severe and progressive disease characterised by obstructive lesions of small pulmonary arteries. Patients with PPH often have mutations in the bone morphogenetic protein receptor type II (BMPR2) gene, whereas some carry mutations in the activin receptor-like kinase 1 (ALK-1) gene, generally associated with hereditary haemorrhagic telangiectasia (HHT) type 2, a vascular dysplasia affecting multiple organs. The aim of this study was to determine whether members of families with PPH and confirmed or probable HHT had ALK-1 mutations. ALK-1 and BMPR2 mutation analysis was performed on deoxyribonucleic acid from affected members of four families with PPH and confirmed or suspected HHT. ALK-1 mutations were identified in all four families and three novel mutations found in exon 10, leading to truncated proteins. In the fourth family, a missense mutation, previously reported in four independent HHT families, was detected in exon 8. Analysis of the BMPR2 gene revealed no exonic mutations in the probands with both PPH and HHT. The present data bring to 10 the number of reported families with primary pulmonary hypertension and hereditary haemorrhagic telangiectasia type 2, representing 16% of the 61 families with known activin receptor-like kinase 1 mutations. Such mutations might predispose to primary pulmonary hypertension, and specialists should be aware of the potential link between these two disorders.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15065824     DOI: 10.1183/09031936.04.00085504

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  23 in total

1.  Regression of pulmonary artery hypertension due to development of a pulmonary arteriovenous malformation.

Authors:  Ashfaq Hasan; B K S Sastry; M A Aleem; Gokul Reddy; Syed Mahmood
Journal:  Indian Heart J       Date:  2014-09-24

2.  Bone morphogenetic protein receptor type II C-terminus interacts with c-Src: implication for a role in pulmonary arterial hypertension.

Authors:  Wai K P Wong; James A Knowles; Jane H Morse
Journal:  Am J Respir Cell Mol Biol       Date:  2005-07-07       Impact factor: 6.914

3.  Successful bosentan therapy for pulmonary arterial hypertension associated with hereditary hemorrhagic telangiectasia.

Authors:  Sung-A Chang; Shin Yi Jang; Chang-Seok Ki; I-Seok Kang; Duk-Kyung Kim
Journal:  Heart Vessels       Date:  2010-12-04       Impact factor: 2.037

Review 4.  Hereditary hemorrhagic telangiectasia, a vascular dysplasia affecting the TGF-beta signaling pathway.

Authors:  Africa Fernández-L; Francisco Sanz-Rodriguez; Francisco J Blanco; Carmelo Bernabéu; Luisa M Botella
Journal:  Clin Med Res       Date:  2006-03

Review 5.  Hereditary haemorrhagic telangiectasia: current views on genetics and mechanisms of disease.

Authors:  S A Abdalla; M Letarte
Journal:  J Med Genet       Date:  2005-05-06       Impact factor: 6.318

6.  A novel regulatory mechanism of the bone morphogenetic protein (BMP) signaling pathway involving the carboxyl-terminal tail domain of BMP type II receptor.

Authors:  Mun Chun Chan; Peter H Nguyen; Brandi N Davis; Nobumichi Ohoka; Hidetoshi Hayashi; Keyong Du; Giorgio Lagna; Akiko Hata
Journal:  Mol Cell Biol       Date:  2007-06-18       Impact factor: 4.272

Review 7.  World Health Organization Group I Pulmonary Hypertension: Epidemiology and Pathophysiology.

Authors:  Kurt W Prins; Thenappan Thenappan
Journal:  Cardiol Clin       Date:  2016-08       Impact factor: 2.213

8.  Analysis of ENG and ACVRL1 genes in 137 HHT Italian families identifies 76 different mutations (24 novel). Comparison with other European studies.

Authors:  Carla Olivieri; Fabio Pagella; Lucia Semino; Luca Lanzarini; Cristina Valacca; Andrea Pilotto; Sabrina Corno; Susi Scappaticci; Guido Manfredi; Elisabetta Buscarini; Cesare Danesino
Journal:  J Hum Genet       Date:  2007-09-05       Impact factor: 3.172

9.  Control of phenotypic plasticity of smooth muscle cells by bone morphogenetic protein signaling through the myocardin-related transcription factors.

Authors:  Giorgio Lagna; Manching M Ku; Peter H Nguyen; Nicole A Neuman; Brandi N Davis; Akiko Hata
Journal:  J Biol Chem       Date:  2007-10-17       Impact factor: 5.157

10.  Bone morphogenetic protein (BMP) and activin type II receptors balance BMP9 signals mediated by activin receptor-like kinase-1 in human pulmonary artery endothelial cells.

Authors:  Paul D Upton; Rachel J Davies; Richard C Trembath; Nicholas W Morrell
Journal:  J Biol Chem       Date:  2009-04-14       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.